Skip to Main Content
Contribute Try STAT+ Today

Bristol-Myers Squibb (BMY), seeking to re-energize its cancer pipeline, is turning to an artificial intelligence startup for help, inking a deal to use the firm’s analytical tools and “real-world” patient data to better target and accelerate clinical trials.

The deal with Concerto HealthAI, a Boston-based firm backed by the $1 billion SymphonyAI fund, is an effort to infuse real-world evidence from medical practices across the U.S. into Bristol’s research. Concerto uses data from CancerLinQ, a national repository of information on cancer patients, to search for patterns that may inform drug development.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.